Can a GLP-1 Cause Gastroparesis? What 13 Documented Cases Actually Show
A 2026 systematic review found 12 published reports of gastroparesis on GLP-1 drugs. What 13 patients can and cannot tell you about your own risk.
Image by azeret33 via Pixabay
Can a GLP-1 Cause Gastroparesis? What 13 Documented Cases Actually Show
Have you seen the headlines about these drugs paralyzing stomachs? Here is what the evidence actually amounts to. Yes, a GLP-1 medication can cause gastroparesis. A systematic review came out in PLoS One this August. The authors searched the entire medical literature and found twelve case reports, covering thirteen patients. All thirteen recovered once the drug was stopped.
Thirteen. That is the whole published record.
What gastroparesis is, and why this drug class would slow a stomach
Gastroparesis means delayed gastric emptying. The stomach still works, and it moves food into the small intestine too slowly, with nothing blocking the exit. Nausea, vomiting, bloating, upper abdominal pain, early fullness, and trouble keeping food down are what people notice.
GLP-1 is a hormone you already make. Agonist means a drug that imitates something your body produces on its own. Your own GLP-1 slows how fast the stomach empties, which is part of how it produces fullness.
So a GLP-1 receptor agonist isn't doing something strange when it slows your gut. Slowing your gut is the mechanism. The harder question is when an expected effect turns into a problem.
What the review actually found
The authors searched PubMed, Embase, Scopus, and Web of Science from inception through October 2025. Twelve case reports met their criteria, describing thirteen patients. Semaglutide came up most often, then liraglutide, dulaglutide, and exenatide.
Most of the patients were women, and most had type 2 diabetes. Cases occurred in non-diabetic people too. Onset ranged from hours to several months after treatment started. One timing pattern kept repeating: symptoms commonly followed a dose escalation or an inappropriate restart of the drug.
Imaging or endoscopy usually showed a stomach holding its contents with no mechanical obstruction. Gastric emptying scintigraphy, which is a scan that times how fast a test meal leaves the stomach, confirmed the delay in selected cases. Care was mostly supportive. A few people needed a nasogastric tube to decompress the stomach. Hospital stays ran three to ten days.
Then the outcome. Stopping the drug resolved symptoms in every reported patient. Those who repeated an emptying study showed normal gastric motility afterward. No deaths and no long term complications were reported. One patient had a longer and more complicated course. That patient had already had several flares of diabetic gastroparesis before ever starting semaglutide.
Why thirteen cases cannot tell you your risk
Thirteen patients is thirteen patients. It is not a rate.
Case reports get written because a case is unusual. Nobody publishes the prescriptions where nothing happened. You can't work backward from a count of case reports to a probability.
The authors say so themselves, and I appreciate that they said it plainly. The true incidence and risk magnitude of GLP-1 induced gastroparesis, in their words, cannot be determined from the current literature. Many of the included reports were conference abstracts with thin clinical detail. Information on comorbidities, medication history, and follow up was inconsistent. The reviewers couldn't always separate new gastroparesis from a flare of gastroparesis someone already had.
Ten of the twelve reports scored low risk of bias on a standard checklist. Careful reporting of thirteen unusual cases gives you no denominator.
One disclosure, seeing as we are being careful about sources. One of the six authors is affiliated with Ferring Pharmaceuticals. That doesn't invalidate a PRISMA review, which is a systematic review done to a standard reporting method, and you should know it anyway.
What the bigger numbers show
The larger dataset here is about SIBO rather than gastroparesis.
A retrospective cohort study used the TriNetX global database. It matched 216,173 adults with type 2 diabetes who started a GLP-1 or dual GLP-1/GIP receptor agonist. The comparison group was the same size, and those patients started other second line diabetes drugs. Within the first year, confirmed small intestinal bacterial overgrowth appeared at 0.177 cases per 1000 patient years in the GLP-1 group, against 0.083 in the comparison group. The hazard ratio was 2.14. The longer-term hazard ratio wasn't statistically significant.
Roughly double sounds alarming until you read the other half. Double of a very small number is still a very small number. Both rates are under one case per thousand patient years.
Small intestinal bacterial overgrowth, or SIBO, is what happens when bacteria that belong further down the digestive tract set up in the small intestine. Motility is why it happens. Your migrating motor complex, or MMC, is a sweeping wave that runs through the small intestine between meals and clears out what is left behind. If that wave slows, bacteria stay put and multiply. A medication that slows transit works against that same wave, which is one common reason SIBO comes back after a clean round of treatment. If a slow gut is already your baseline, methane predominant overgrowth belongs on the list too, since the methane itself slows transit further.
In clinic, the people who run into trouble on these drugs are rarely the ones on a stable dose. They are the ones who just stepped up. Or the ones who paused for a few weeks, then restarted where they left off instead of where they should have. The published cases show the same timing.
What to bring to your prescriber
Nothing here is a reason to stop a prescription. Every one of those thirteen patients stopped under medical supervision. Stopping a diabetes medication on your own carries its own risk, and a blog post can't see your chart.
If you are on a GLP-1 and your gut is struggling, a few things are useful to bring to your prescriber.
-
The timing. If you write down when the symptoms started relative to your last dose change, you hand your prescriber the single most useful detail. Symptoms that began within days or weeks of a step up are the pattern the published cases keep showing.
-
Whether you restarted. If you paused the medication and went back on at your old dose rather than retitrating, that belongs in the conversation.
-
What the symptoms actually are. Nausea that passes is common with this drug class. Vomiting, being unable to keep fluids down, or losing weight faster than you intended is a different conversation.
-
Your history. If you already had diabetic gastroparesis or autonomic neuropathy, which is nerve damage affecting automatic functions like digestion, the review authors advise more caution and earlier consideration of alternatives.
Titration is what your prescriber actually controls. Gradual dose increases and careful patient selection are what the authors recommend, and it lines up with what I see. The SIBO and motility hub collects the rest of the picture.
This is education, and it isn't a substitute for a clinician who can see your history alongside your symptoms.
If the motility side of this is what you want to understand properly, the Motility Taster covers it. It walks through how the migrating motor complex works, what suppresses it, and why it decides who relapses.
FAQ
Does everyone on a GLP-1 get delayed stomach emptying?
Some slowing of gastric emptying is an expected effect of this drug class, since that slowing is part of how the medication produces fullness. Symptomatic gastroparesis, meaning slowing bad enough to cause vomiting and an inability to tolerate food, is a different matter and appears to be uncommon. The published literature carries no incidence figure for it.
Is gastroparesis from a GLP-1 permanent?
In the thirteen published cases, it wasn't. Symptoms resolved after the drug was discontinued, and patients who repeated a gastric emptying study showed normal motility afterward. Thirteen patients is a small sample, so treat that as reassuring rather than settled.
Which GLP-1 drug is reported most often?
Semaglutide appeared most frequently in the reviewed cases, followed by liraglutide, dulaglutide, and exenatide. That ordering likely tracks prescribing volume as much as anything about the individual drugs. A count of case reports can't rank a drug class by risk.
Can a GLP-1 cause SIBO?
A cohort study of 216,173 matched pairs found more newly diagnosed small intestinal bacterial overgrowth in the first year on these drugs, at 0.177 versus 0.083 cases per 1000 patient years. The relative difference is roughly double, and the absolute risk in both groups is small. Slowed motility is the proposed explanation.
Should I stop my GLP-1 if my stomach feels slow?
Not on your own. Talk to whoever prescribed it, and bring the timing of your symptoms relative to any dose change. Discontinuation was how the reported cases resolved, and every one of those decisions was made with a clinician involved.
What is the migrating motor complex?
It is a wave of muscular activity that sweeps through the small intestine between meals, clearing out debris and leftover bacteria. It runs only when you aren't digesting, which is why constant snacking suppresses it. When it stalls, bacteria that should have been moved along stay in place, and that is a common reason SIBO returns after treatment.
References
- 1.
- 2.
